Replimune (REPL) widens FY 2026 loss as FDA accepts RP1 melanoma BLA
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Replimune Group, Inc. reported fiscal fourth quarter and full-year 2026 results and a corporate update. For the year ended March 31, 2026, operating expenses were $319.9 million, leading to a net loss of $313.9 million, or $3.38 per share.
Cash, cash equivalents and short-term investments were $268.9 million as of March 31, 2026, and the company expects this to fund operations into the first quarter of calendar 2027. The FDA accepted the resubmitted BLA for lead candidate RP1 in advanced melanoma with a goal date of August 2, 2026 and an advisory committee meeting expected in late July.
Positive
- FDA accepted RP1 BLA resubmission with clear review timeline: The agency deemed the RP1 BLA resubmission a complete class 1 response, set a goal date of August 2, 2026, and notified the company to expect an advisory committee meeting in late July, advancing RP1 toward potential approval in advanced melanoma.
Negative
- Higher losses and reduced balance sheet strength: Net loss widened to $313.9 million for the year ended March 31, 2026, compared with $247.3 million a year earlier, while cash, cash equivalents and short-term investments declined to $268.9 million from $483.8 million, narrowing financial flexibility.
Insights
FDA BLA acceptance for RP1 is a key milestone, offset by higher cash burn and losses.
Replimune remains a clinical-stage company with no product revenue, so the main operational story is spending and regulatory progress. Operating expenses reached $319.9M for the year ended March 31, 2026, driving a net loss of $313.9M.
The FDA’s acceptance of the resubmitted BLA for RP1 in advanced melanoma, with a goal date of August 2, 2026 and an advisory committee meeting in late July, represents a pivotal regulatory event. It moves RP1 closer to potential approval but does not guarantee it.
Cash, cash equivalents and short-term investments of $268.9M and stated runway into the first quarter of calendar 2027 suggest a finite funding window that includes scale-up for potential commercialization. Subsequent company disclosures will be important to see how the FDA review and any commercialization plans affect spending and capital needs.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Operating expenses: $319.9M
Net loss: $313.9M
Net loss per share: $3.38 per share
+5 more
8 metrics
Operating expenses
$319.9M
Total operating expenses for year ended March 31, 2026
Net loss
$313.9M
Net loss for year ended March 31, 2026
Net loss per share
$3.38 per share
Basic and diluted for year ended March 31, 2026
Cash and investments
$268.9M
Cash, cash equivalents and short-term investments as of March 31, 2026
Weighted average shares
92,803,711 shares
Weighted average common shares outstanding, year ended March 31, 2026
RP1 BLA goal date
August 2, 2026
FDA goal date for RP1 BLA in advanced melanoma
Working capital
$220.9M
Working capital as of March 31, 2026
Total stockholders’ equity
$166.2M
Stockholders’ equity as of March 31, 2026
Key Terms
Biologics License Application, advanced melanoma, oncolytic immunotherapies, fusogenic protein, +2 more
6 terms
Biologics License Application regulatory
"the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for RP1"
A biologics license application is a formal request submitted to regulatory authorities seeking approval to market a new biological medicine, such as vaccines or treatments made from living organisms. It is a comprehensive review process that evaluates the safety, effectiveness, and manufacturing quality of the product. For investors, receiving approval signals that a biological therapy can be sold to the public, potentially leading to revenue growth and market success.
advanced melanoma medical
"RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma"
Advanced melanoma is a form of skin cancer that has grown beyond the original spot or cannot be removed with surgery, often spreading to other parts of the body. For investors, it matters because this stage drives demand for more complex treatments, ongoing drug development, clinical trial results, and regulatory decisions—similar to how a house fire that spreads beyond one room requires a different, more costly response than a small contained blaze.
oncolytic immunotherapies medical
"a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies"
Oncolytic immunotherapies are treatments that use viruses or virus-like agents engineered to infect and destroy cancer cells while also waking up the immune system to attack tumors. Think of them as a Trojan horse that both breaks cancer’s defenses and calls in reinforcements; for investors, they matter because successful therapies can change standard cancer care, offer high commercial upside but come with steep scientific, regulatory and trial-stage risks that make outcomes binary and valuation-sensitive.
fusogenic protein medical
"engineered and genetically armed with a fusogenic protein (GALV- R-) and GM-CSF intended to maximize tumor killing potency"
GM-CSF medical
"engineered and genetically armed with a fusogenic protein (GALV- R-) and GM-CSF intended to maximize tumor killing potency"
GM‑CSF is a naturally occurring immune signaling protein that tells certain white blood cells to grow, move and fight infection — like a traffic cop directing immune cells to where they’re needed. Investors care because drugs that boost or block GM‑CSF can treat cancers, inflammatory conditions or infectious diseases, so clinical trial results, approvals, dosing and safety concerns can materially affect a biotech or pharmaceutical company’s clinical and commercial prospects.
anti-CTLA-4 antibody-like molecule medical
"RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP R- and GM-CSF"
Earnings Snapshot
Net loss: $313.9M · Guidance included
Year ended March 31, 2026
Net loss
$313.9M
Operating expenses
$319.9M
Net loss per share (basic and diluted)
$3.38
Cash, cash equivalents and short-term investments
$268.9M
Guidance
The company believes existing cash, cash equivalents and short-term investments will fund operations into the first quarter of calendar 2027.
FAQ
What did Replimune (REPL) report for its fiscal year 2026 net loss?
Replimune reported a fiscal year 2026 net loss of $313.9 million. This compares with a net loss of $247.3 million for the prior year, reflecting higher operating expenses as the company advances its oncolytic immunotherapy pipeline.
How much did Replimune (REPL) spend on operating expenses in fiscal 2026?
Replimune’s operating expenses totaled $319.9 million for the year ended March 31, 2026. This includes research and development and selling, general and administrative costs tied to progressing RP1, RP2 and broader platform activities.
What is Replimune’s (REPL) cash position and runway as of March 31, 2026?
As of March 31, 2026, Replimune had $268.9 million in cash, cash equivalents and short-term investments. Management believes this will fund operations into the first quarter of calendar 2027, including potential commercialization scale-up for RP1 and general corporate purposes.
What progress has Replimune (REPL) made with the FDA on RP1?
The FDA accepted Replimune’s resubmitted BLA for RP1 in advanced melanoma as a complete class 1 response. The agency set a goal date of August 2, 2026 and indicated an advisory committee meeting is expected in late July, marking a key regulatory step.
Does Replimune (REPL) provide guidance on when its cash runway ends?
Replimune states that, under its current operating plan, existing cash, cash equivalents and short-term investments should fund operations into the first quarter of calendar 2027. This estimate includes potential RP1 commercialization scale-up and excludes any potential revenue.
What are Replimune’s (REPL) lead product candidates RP1 and RP2?
Replimune’s lead candidate RP1 is an engineered herpes simplex virus designed to enhance tumor cell killing and immune activation. RP2 builds on RP1 by also expressing an anti-CTLA-4 antibody-like molecule, aiming to focus potent immune activity within tumors and draining lymph nodes.